Highest-materiality recent filing
CV Sciences Q2 2026 revenue down 17.5% to $3.0M; adjusted EBITDA turns negative
Revenue $3.0M, down 17.5% YoY from $3.6M; gross margin 48.6% vs 50.9% prior year.
CV Sciences shareholders reject reverse stock split; three directors elected
Proposal 2 (reverse stock split up to 1-for-800) failed: 48.5M for, 59.6M against, 8.1M abstain.
CV Sciences FY2025 revenue down 12% to $13.8M; adjusted EBITDA loss narrows to $0.3M
Revenue $13.8M for FY2025 vs $15.7M in 2024, a 12.2% decline on lower volume and regulatory headwinds.
CV Sciences restructures notes: adds conversion at $0.06/share, principal to $2.256M
Outstanding note principal increased 20% to $2,256,000; monthly redemption obligation eliminated.
Revenue $3.3M, down 16% YoY from $3.9M; net revenue from products launched since Jan 2023 contributed 39%.
CV Sciences issues $600K secured note with $300K net proceeds; potential add'l $750K
Issued $600K secured promissory note with 25% OID ($150K) plus $150K modification fee; net proceeds $300K.
CV Sciences amends $1.6M secured note, extends maturity to 2027, defers payments
Original $1.6M note issued Feb 2025 with $400K OID; outstanding balance $1.28M after $320K payments.
CV Sciences Q2 revenue $3.6M (-8% YoY); first positive adjusted EBITDA in six years
Revenue $3.6M, down 8% from $4.0M in Q2 2024; units sold down 7%, avg price down 2.8%.
CV Sciences FY2024 revenue $15.7M (-1.9% YoY), operating loss $2.2M vs income $3.4M in 2023
Revenue $15.7M vs $16.0M in 2023; Q4 revenue $3.9M (+2.2% YoY).
CV Sciences initiates arbitration against former legal counsel Procopio over faulty RSU tax advice
Arbitration filed Feb 12, 2025; claims Procopio provided incorrect tax advice on CEO Mona's RSU settlement.
CV Sciences disputes Extract Labs acquisition termination by Sellers; evaluating options
On Feb 5, 2025, Extract Labs owners informed CV Sciences they cannot close due to alleged failure to obtain bank consent, purportedly terminating the Stock Purchase Agreement.
CV Sciences agrees to acquire Extract Labs for $1.4M cash and stock, plus earnout
Total consideration: $400K cash + $1M in CVSI stock at closing; up to $600K earnout in stock.
Revenue $4.0M flat YoY and sequentially; B2C sales up 4% offset by B2B decline of 3%.
CV Sciences acquires Elevated Softgels for up to $1M; plans in-sourcing of +PlusCBD production
Total consideration up to $1,000,000: $100k cash, 17.4M shares ($700k), plus earnout up to $200k.
CV Sciences Q1 2024 revenue $4.0M, gross margin 46.3%, operating loss $0.6M
Revenue $4.0M, down 4% YoY from $4.1M, up sequentially from $3.8M in Q4 2023.
CV Sciences acquires Cultured Foods for up to $535K to enter plant-based food market
Total consideration up to $535K: $175K cash, 7.07M shares valued at $250K, plus up to $110K earn-out.
CV Sciences Q3 revenue $4.1M (+9% YoY); margin expands; signs LOI for European acquisition
Revenue $4.1M, +9% YoY from $3.8M; gross margin 45.1% vs 41.6%.
CV Sciences Q2 revenue $4.0M; gross margin 43.3%, operating loss narrows to $1.1M
Revenue of $4.0M, down 4% YoY from $4.1M; units sold down 16%, offset by higher average selling price.
CV Sciences Q1 revenue down 7% to $4.1M; gross margin improves to 43% vs 26% YoY
Revenue $4.1M vs $4.4M YoY; sequential increase of 7% from Q4 2022.
CV Sciences FY2022 revenue $16.2M, down 19% YoY; operating loss narrows to $6.8M
Revenue $16.2M for FY2022 vs $20.0M in 2021 (-19%); Q4 revenue $3.9M, up 3% sequentially.
CV Sciences Q3 2022 revenue down 27% YoY to $3.8M, operating loss narrowed to $0.9M
Revenue $3.8M, down 27% from $5.1M; gross margin 41.6% vs 46.2%.
CV Sciences reaches preliminary settlement of six derivative lawsuits; court grants approval
Court granted preliminary approval on Sept 21, 2022; final hearing set for Nov 14, 2022.
CV Sciences issues $2M secured note, extinguishes convertible debt to reduce dilution
Entered $2M secured promissory note with Streeterville Capital; net proceeds $1.59M after $400K OID and $10K fees.
CV Sciences Q2 2022 revenue falls 19% to $4.1M; gross margin drops to 30.7%
Revenue $4.1M down from $5.1M YoY; units sold decreased 5%.
CV Sciences resolves note default via conversion; investor converts $152K into 3.75M shares at $0.04
CV Sciences failed to repay $130K principal plus interest on Nov 2021 senior convertible note at May 17, 2022 maturity, causing default.
CV Sciences defaults on $1.06M convertible note; enters forbearance until June 1, 2022
Failed to pay $130K principal plus interest on May 17, 2022 maturity date, triggering default.
CV Sciences Q1 revenue $4.4M (-8% YoY); operating loss narrows to $1.5M on ERC benefit
Revenue $4.4M, down 8% from $4.8M in Q1 2021; units shipped up 3% offset by discounts and mix.
CV Sciences raises $700K via convertible preferred and warrants; seeks reverse split up to 1:400
Issued 700 shares of convertible preferred ($1,000 stated value) convertible into 10M shares at $0.07/sh, plus warrants for 10M shares at $0.10/sh.
CV Sciences reports FY2021 revenue down 18% to $20.0M; loss narrows to $18.4M
Revenue of $20.0M for FY2021, down 18% from $24.4M in 2020.
CV Sciences Q3 2021 revenue down 8% to $5.1M; cash drops to $1.7M
Revenue $5.1M vs $5.6M YoY (-8%); operating loss $3.0M vs $3.2M.
On October 21, 2022, the Board of Directors of CV Sciences, Inc. (the "Company") appointed William McCorkle as a director on the Company’s Board of Directors (the “Board”).
On July 21, 2022, Dr. Joseph C. Maroon resigned as a member of the Board of Directors of the Company.
On July 21, 2022, the Board of Directors of CV Sciences, Inc. (the "Company") appointed Dr. Jamie Corroon Jr., ND, MPH as a director on the Company’s Board of Directors (the “Board”).
On September 24, 2021, Dr. Douglas MacKay submitted his resignation from his position as CV Sciences, Inc.'s Senior Vice President, Scientific and Regulatory Affairs.
Max materiality 0.75 · Median 0.60 · Most common event earnings